Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Plasmid DNA Manufacturing Market Growth & Trends
The global plasmid DNA manufacturing market size is expected to reach USD 1.51 billion by 2030, registering a CAGR of 13.71% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.
According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world’s first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.
Circular DNA is used in India’s ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.
Plasmid DNA Manufacturing Market Report Highlights
Plasmid DNA Manufacturing Market Growth & Trends
The global plasmid DNA manufacturing market size is expected to reach USD 1.51 billion by 2030, registering a CAGR of 13.71% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.
According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world’s first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.
Circular DNA is used in India’s ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.
Plasmid DNA Manufacturing Market Report Highlights
- The GMP grade type segment held the largest revenue share in 2021. GMP-grade plasmid DNAs are broadly utilized in pre-clinical trials in gene therapy or vaccination including biodistribution and toxicology studies
- The clinical therapeutics segment dominated the global industry in 2021 owing to the increased importance of plasmid DNA for clinical research applications in genetic vaccination
- The infectious diseases segment held a significant revenue in 2021. DNA plasmid is effectively utilized in the treatment of several infectious disorders as it delivers a strong immunity via vaccine antigen and prevents pathogen infections
- The cell & gene therapy application segment led the industry in 2021 owing to the high demand for gene therapy for the treatment of several inherited diseases and genetic disorders
- North America was the dominant regional market in 2021 due to improved healthcare infrastructure, high disposable income, presence of a substantial number of centers and institutes that are engaged in R&D of advanced therapies, and increased adoption of advanced therapies in the region
- Asia Pacific is anticipated to register the fastest CAGR during the forecast years on account of the increasing R&D activities in this field and the presence of key players
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Summary
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Information Procurement
2.2. Information Or Data Analysis
2.3. Market Model
2.3.1. Market Analysis, By plasmid DNA manufacturing
2.3.2. Market Study, By Grade
2.3.3. Regional Analysis
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation & Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing number of patients opting for gene therapy
3.2.1.2. Robust Pipeline For Gene Therapies
3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By market players
3.2.1.2. Increasing demand for plasmid DNA in various medical therapies
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
3.3. Covid-19 Impact
3.4. Penetration & Growth Prospect Mapping For Vector Type, 2021
3.5. Industry Analysis - Porter’s Five Forces
3.6. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.7. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2021
3.8. Manufacturer’s Landscape
3.9. Plasmid DNA Manufacturing Capacity Mapping Analysis
3.10. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.11. List Of Plasmid DNA Manufacturers
CHAPTER 4. PLASMID DNA MANUFACTURING MARKET: STRATEGIC ALLIANCES
4.1. Strategic Approaches For Market Scale-Up
4.1.1. Partnership Models
4.1.2. Acquisition
4.1.3. Minority Interest (Ownership)
4.1.4. Joint Venture
4.1.4. Alliance
4.1.6. Franchise
4.2. Collaborations In Plasmid DNA Manufacturing Market
CHAPTER 5. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY GRADE, 2018 - 2030 (USD MILLION)
5.1. Plasmid DNA Manufacturing Market: Grade Movement Analysis
5.2. R&D Grade
5.2.1. Global R&D Grade Market 2018 - 2030 (USD Million)
5.3. GMP Grade
5.3.1. Global GMP Grade Market 2018 - 2030 (USD Million)
CHAPTER 6. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY DEVELOPMENT PHASE, 2018 - 2030 (USD MILLION)
6.1. Plasmid DNA Manufacturing Market: Development Phase Movement Analysis
6.2. Pre-clinical Therapeutics
6.2.1. Global Pre-clinical Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
6.3. Clinical Therapeutics
6.3.1. Global Clinical Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
6.4. Marketed Therapeutics
6.4.1. Global Marketed Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 7. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2018 - 2030 (USD MILLION)
7.1. Plasmid DNA Manufacturing Market: Application Movement Analysis
7.2. DNA Vaccines
7.2.1. Global Plasmid DNA Manufacturing Market For DNA Vaccines, 2018 - 2030 (USD Million)
7.3. Cell & Gene Therapy
7.3.1. Global Plasmid DNA Manufacturing Market For Cell & Gene Therapy 2018 - 2030 (USD Million)
7.4. Immunotherapy
7.4.1. Global Plasmid DNA Manufacturing Market For Immunotherapy, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Global Plasmid DNA Manufacturing Market For Others, 2018 - 2030 (USD Million)
CHAPTER 8. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY DISEASE, 2018 - 2030 (USD MILLION)
8.1. Plasmid DNA Manufacturing Market: Disease Movement Analysis
8.2. Cancer
8.2.1. Global Plasmid DNA Manufacturing Market For Cancer, 2018 - 2030 (USD Million)
8.3. Genetic Disorders
8.3.1. Global Plasmid DNA Manufacturing Market For Genetic Disorders, 2018 - 2030 (USD Million)
8.4. Infectious Diseases
8.4.1. Global Plasmid DNA Manufacturing Market For Infectious Diseases, 2018 - 2030 (USD Million)
CHAPTER 9. REGIONAL BUSINESS ANALYSIS
9.1. Plasmid DNA Manufacturing Market Share By Regional, 2021 & 2030
9.1.1 North America
9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.2 U.S.
9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.3 Canada
9.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2 Europe
9.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.2 U.K.
9.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.3 Germany
9.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.4 France
9.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.5 Spain
9.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.6 Italy
9.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3 Asia Pacific
9.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.2 Japan
9.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.3 China
9.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.4 India
9.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.5 Australia
9.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4 Latin America
9.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.2 Brazil
9.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.3 Mexico
9.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.4 Argentina
9.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5 Middle East & Africa
9.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.2 South Africa
9.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.3 Saudi Arabia
9.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.5 United Arab Emirates
9.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE ANALYSIS
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Manufacturer’s Landscape
10.4. Vendor Landscape
10.5. Key Initiatives & Strategic Alliances Analysis
10.5.1. Merger & Acquisition Deals
10.5.2. Collaborations & Partnerships
10.5.3. Business Expansion
10.5.4. Technology Collaborations
10.6. Public Companies Analysis
10.7. Private Companies
10.7.1. List of Key Emerging Companies
10.7.2. Market Participation Categorization (Market Operations & Weakness)
10.7.3. Strategy Framework
10.8. Company Profiles
10.8.1. Charles River Laboratories
10.8.1.1. Company Overview
10.8.1.2. Product Benchmarking
10.8.1.3. Strategic Initiatives
10.8.2. VGXI, Inc
10.8.2.1. Company Overview
10.8.2.2. Product Benchmarking
10.8.2.3. Strategic Initiatives
10.8.3. Aldevron.
10.8.3.1. Company Overview
10.8.3.2. Product Benchmarking
10.8.3.3. Strategic Initiatives
10.8.4. KANEKA CORPORATION
10.8.4.1. Company Overview
10.8.4.2. Product Benchmarking
10.8.4.3. Strategic Initiatives
10.8.5. Nature Technology
10.8.5.1. Company Overview
10.8.5.2. Product Benchmarking
10.8.5.3. Strategic Initiatives
10.8.6. Cell and Gene Therapy Catapult
10.8.6.1. Company Overview
10.8.6.2. Product Benchmarking
10.8.6.3. Strategic Initiatives
10.8.7. Eurofins Genomics
10.8.7.1. Company Overview
10.8.7.2. Product Benchmarking
10.8.8. Lonza
10.8.8.1. Company Overview
10.8.8.2. Product Benchmarking
10.8.8.3. Strategic Initiatives
10.8.9. Luminous BioSciences, LLC
10.8.9.1. Company Overview
10.8.9.2. Product Benchmarking
10.8.9.3. Strategic Initiatives
10.8.10. Akron Biotech
10.8.10.1. Company Overview
10.8.10.2. Product Benchmarking
10.8.10.3. Strategic Initiatives
1.1. Market Summary
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Information Procurement
2.2. Information Or Data Analysis
2.3. Market Model
2.3.1. Market Analysis, By plasmid DNA manufacturing
2.3.2. Market Study, By Grade
2.3.3. Regional Analysis
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation & Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing number of patients opting for gene therapy
3.2.1.2. Robust Pipeline For Gene Therapies
3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By market players
3.2.1.2. Increasing demand for plasmid DNA in various medical therapies
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
3.3. Covid-19 Impact
3.4. Penetration & Growth Prospect Mapping For Vector Type, 2021
3.5. Industry Analysis - Porter’s Five Forces
3.6. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.7. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2021
3.8. Manufacturer’s Landscape
3.9. Plasmid DNA Manufacturing Capacity Mapping Analysis
3.10. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.11. List Of Plasmid DNA Manufacturers
CHAPTER 4. PLASMID DNA MANUFACTURING MARKET: STRATEGIC ALLIANCES
4.1. Strategic Approaches For Market Scale-Up
4.1.1. Partnership Models
4.1.2. Acquisition
4.1.3. Minority Interest (Ownership)
4.1.4. Joint Venture
4.1.4. Alliance
4.1.6. Franchise
4.2. Collaborations In Plasmid DNA Manufacturing Market
CHAPTER 5. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY GRADE, 2018 - 2030 (USD MILLION)
5.1. Plasmid DNA Manufacturing Market: Grade Movement Analysis
5.2. R&D Grade
5.2.1. Global R&D Grade Market 2018 - 2030 (USD Million)
5.3. GMP Grade
5.3.1. Global GMP Grade Market 2018 - 2030 (USD Million)
CHAPTER 6. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY DEVELOPMENT PHASE, 2018 - 2030 (USD MILLION)
6.1. Plasmid DNA Manufacturing Market: Development Phase Movement Analysis
6.2. Pre-clinical Therapeutics
6.2.1. Global Pre-clinical Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
6.3. Clinical Therapeutics
6.3.1. Global Clinical Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
6.4. Marketed Therapeutics
6.4.1. Global Marketed Therapeutics Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 7. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2018 - 2030 (USD MILLION)
7.1. Plasmid DNA Manufacturing Market: Application Movement Analysis
7.2. DNA Vaccines
7.2.1. Global Plasmid DNA Manufacturing Market For DNA Vaccines, 2018 - 2030 (USD Million)
7.3. Cell & Gene Therapy
7.3.1. Global Plasmid DNA Manufacturing Market For Cell & Gene Therapy 2018 - 2030 (USD Million)
7.4. Immunotherapy
7.4.1. Global Plasmid DNA Manufacturing Market For Immunotherapy, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Global Plasmid DNA Manufacturing Market For Others, 2018 - 2030 (USD Million)
CHAPTER 8. PLASMID DNA MANUFACTURING MARKET: SEGMENT ANALYSIS, BY DISEASE, 2018 - 2030 (USD MILLION)
8.1. Plasmid DNA Manufacturing Market: Disease Movement Analysis
8.2. Cancer
8.2.1. Global Plasmid DNA Manufacturing Market For Cancer, 2018 - 2030 (USD Million)
8.3. Genetic Disorders
8.3.1. Global Plasmid DNA Manufacturing Market For Genetic Disorders, 2018 - 2030 (USD Million)
8.4. Infectious Diseases
8.4.1. Global Plasmid DNA Manufacturing Market For Infectious Diseases, 2018 - 2030 (USD Million)
CHAPTER 9. REGIONAL BUSINESS ANALYSIS
9.1. Plasmid DNA Manufacturing Market Share By Regional, 2021 & 2030
9.1.1 North America
9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.2 U.S.
9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.3 Canada
9.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2 Europe
9.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.2 U.K.
9.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.3 Germany
9.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.4 France
9.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.5 Spain
9.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.6 Italy
9.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3 Asia Pacific
9.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.2 Japan
9.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.3 China
9.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.4 India
9.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.5 Australia
9.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4 Latin America
9.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.2 Brazil
9.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.3 Mexico
9.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.4 Argentina
9.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5 Middle East & Africa
9.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.2 South Africa
9.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.3 Saudi Arabia
9.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.5 United Arab Emirates
9.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE ANALYSIS
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Manufacturer’s Landscape
10.4. Vendor Landscape
10.5. Key Initiatives & Strategic Alliances Analysis
10.5.1. Merger & Acquisition Deals
10.5.2. Collaborations & Partnerships
10.5.3. Business Expansion
10.5.4. Technology Collaborations
10.6. Public Companies Analysis
10.7. Private Companies
10.7.1. List of Key Emerging Companies
10.7.2. Market Participation Categorization (Market Operations & Weakness)
10.7.3. Strategy Framework
10.8. Company Profiles
10.8.1. Charles River Laboratories
10.8.1.1. Company Overview
10.8.1.2. Product Benchmarking
10.8.1.3. Strategic Initiatives
10.8.2. VGXI, Inc
10.8.2.1. Company Overview
10.8.2.2. Product Benchmarking
10.8.2.3. Strategic Initiatives
10.8.3. Aldevron.
10.8.3.1. Company Overview
10.8.3.2. Product Benchmarking
10.8.3.3. Strategic Initiatives
10.8.4. KANEKA CORPORATION
10.8.4.1. Company Overview
10.8.4.2. Product Benchmarking
10.8.4.3. Strategic Initiatives
10.8.5. Nature Technology
10.8.5.1. Company Overview
10.8.5.2. Product Benchmarking
10.8.5.3. Strategic Initiatives
10.8.6. Cell and Gene Therapy Catapult
10.8.6.1. Company Overview
10.8.6.2. Product Benchmarking
10.8.6.3. Strategic Initiatives
10.8.7. Eurofins Genomics
10.8.7.1. Company Overview
10.8.7.2. Product Benchmarking
10.8.8. Lonza
10.8.8.1. Company Overview
10.8.8.2. Product Benchmarking
10.8.8.3. Strategic Initiatives
10.8.9. Luminous BioSciences, LLC
10.8.9.1. Company Overview
10.8.9.2. Product Benchmarking
10.8.9.3. Strategic Initiatives
10.8.10. Akron Biotech
10.8.10.1. Company Overview
10.8.10.2. Product Benchmarking
10.8.10.3. Strategic Initiatives
LIST OF TABLES
TABLE 1 Global Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 2 Global Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 3 Global Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 4 Global Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 5 North America Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 6 North America Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 7 North America Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 8 North America Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 9 U.S. Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 10 U.S. Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 11 U.S. Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 12 U.S. Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 13 Canada Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 14 Canada Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 15 Canada Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 16 Canada Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 17 Europe Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 18 Europe Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 19 Europe Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 20 Europe Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 21 Germany Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 22 Germany Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 23 Germany Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 24 Germany Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 25 U.K. Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 26 U.K. Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 27 U.K. Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 28 U.K. Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 29 France Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 30 France Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 31 France Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 32 France Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 33 Spain Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 34 Spain Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 35 Spain Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 36 Spain Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 37 Italy Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 38 Italy Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 39 Italy Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 40 Italy Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 41 Asia Pacific Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 42 Asia Pacific Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 43 Asia Pacific Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 44 Asia Pacific Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 45 Japan Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 46 Japan Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 47 Japan Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 48 Japan Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 49 China Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 50 China Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 51 China Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 52 China Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 53 India Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 54 India Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 55 India Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 56 India Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 57 Australia Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 58 Australia Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 59 Australia Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 60 Australia Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 61 South Korea Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 62 South Korea Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 63 South Korea Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 64 South Korea Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 65 Latin America Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 66 Latin America Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 67 Latin America Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 68 Latin America Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 69 Brazil Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 70 Brazil Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 71 Brazil Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 72 Brazil Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 73 Mexico Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 74 Mexico Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 75 Mexico Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 76 Mexico Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 77 Argentina Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 78 Argentina Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 79 Argentina Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 80 Argentina Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 81 Middle East and Africa Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 82 Middle East and Africa Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 83 Middle East and Africa Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 84 Middle East and Africa Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 85 South Africa Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 86 South Africa Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 87 South Africa Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 88 South Africa Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 89 Saudi Arabia Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 90 Saudi Arabia Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 91 Saudi Arabia Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 92 Saudi Arabia Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 93 UAE Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 94 UAE Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 95 UAE Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 96 UAE Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 1 Global Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 2 Global Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 3 Global Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 4 Global Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 5 North America Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 6 North America Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 7 North America Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 8 North America Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 9 U.S. Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 10 U.S. Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 11 U.S. Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 12 U.S. Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 13 Canada Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 14 Canada Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 15 Canada Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 16 Canada Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 17 Europe Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 18 Europe Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 19 Europe Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 20 Europe Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 21 Germany Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 22 Germany Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 23 Germany Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 24 Germany Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 25 U.K. Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 26 U.K. Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 27 U.K. Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 28 U.K. Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 29 France Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 30 France Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 31 France Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 32 France Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 33 Spain Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 34 Spain Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 35 Spain Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 36 Spain Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 37 Italy Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 38 Italy Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 39 Italy Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 40 Italy Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 41 Asia Pacific Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 42 Asia Pacific Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 43 Asia Pacific Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 44 Asia Pacific Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 45 Japan Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 46 Japan Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 47 Japan Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 48 Japan Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 49 China Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 50 China Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 51 China Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 52 China Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 53 India Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 54 India Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 55 India Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 56 India Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 57 Australia Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 58 Australia Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 59 Australia Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 60 Australia Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 61 South Korea Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 62 South Korea Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 63 South Korea Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 64 South Korea Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 65 Latin America Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 66 Latin America Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 67 Latin America Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 68 Latin America Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 69 Brazil Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 70 Brazil Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 71 Brazil Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 72 Brazil Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 73 Mexico Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 74 Mexico Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 75 Mexico Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 76 Mexico Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 77 Argentina Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 78 Argentina Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 79 Argentina Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 80 Argentina Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 81 Middle East and Africa Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 82 Middle East and Africa Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 83 Middle East and Africa Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 84 Middle East and Africa Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 85 South Africa Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 86 South Africa Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 87 South Africa Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 88 South Africa Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 89 Saudi Arabia Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 90 Saudi Arabia Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 91 Saudi Arabia Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 92 Saudi Arabia Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
TABLE 93 UAE Plasmid DNA Manufacturing Market, by Grade, 2018 - 2030 (USD Million)
TABLE 94 UAE Plasmid DNA Manufacturing Market, by Development Phase, 2018 - 2030 (USD Million)
TABLE 95 UAE Plasmid DNA Manufacturing Market, by Application, 2018 - 2030 (USD Million)
TABLE 96 UAE Plasmid DNA Manufacturing Market, by Disease, 2018 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Market snapshot, 2021 (USD Million)
FIG. 3 Market research process
FIG. 4 Information procurement
FIG. 5 Primary research pattern
FIG. 6 Primary research pattern
FIG. 7 Market research approaches
FIG. 8 Value-chain-based sizing & forecasting
FIG. 9 QFD modeling for market share assessment
FIG. 10 Market formulation & validation
FIG. 11 QFD model assessment for plasmid DNA type
FIG. 12 Gene therapy approvals versus clinical trials
FIG. 13 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
FIG. 14 Distribution of the sponsors of advanced therapies clinical trials, 2016
FIG. 15 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
FIG. 16 Gene therapy approvals versus clinical trials
FIG. 17 Regional analysis for rare disease genetic testing market
FIG. 18 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
FIG. 19 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2021
FIG. 20 Market trends & outlook
FIG. 21 Market segmentation & scope
FIG. 22 Market driver relevance analysis (Current & future impact)
FIG. 23 Gene therapy clinical trials
FIG. 24 Viral vectors used in clinical trials
FIG. 25 Key strategies by market players to drive success in gene therapy arena
FIG. 26 Recent and upcoming approved gene transfer-mediated programs
FIG. 27 Market restraint relevance analysis (Current & future impact)
FIG. 28 Various ethical questions raised by gene therapy
FIG. 29 Major challenges in large-scale vector manufacturing
FIG. 30 Plasmid production: Challenges & solutions
FIG. 31 Penetration & growth prospect mapping for vector type, 2021
FIG. 32 Porter’s Five Forces Analysis
FIG. 33 SWOT analysis, by factor (Political & Legal, Economic and Technological)
FIG. 34 Penetration & growth prospect mapping for prominent industry players, 2021
FIG. 35 Plasmid DNA Manufacturing Landscape
FIG. 36 List of plasmid DNA manufacturers
FIG. 37 Comparison of costs estimated by campaign, day rate, and hybrid models
FIG. 38 Campaign model for viral vector production
FIG. 39 Gene Therapy Manufacturing Facilities: Trends & Types
FIG. 40 Gene Therapy Road Map: Key External Trends
FIG. 41 Strategic Approaches for Market Scale-Up
FIG. 42 Plasmid DNA manufacturing market: Grade outlook key takeaways
FIG. 43 Plasmid DNA manufacturing market: Grade movement analysis
FIG. 44 Global R & D market 2018 - 2030 (USD Million)
FIG. 45 Global GMP market 2018 - 2030 (USD Million)
FIG. 46 Plasmid DNA manufacturing market: Development phase outlook and key takeaways
FIG. 47 Global plasmid DNA manufacturing market: Development phase movement analysis
FIG. 48 Global pre-Clinical therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 49 Global clinical therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 50 Global marketed therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 51 Plasmid DNA manufacturing market: Application outlook and key takeaways
FIG. 52 Plasmid DNA manufacturing market: Application movement analysis
FIG. 53 Global plasmid DNA manufacturing market for DNA vaccines 2018 - 2030 (USD Million)
FIG. 54 Global plasmid DNA manufacturing market for cell and gene therapy 2018 - 2030 (USD Million)
FIG. 55 Global plasmid DNA manufacturing market for immunotherapy 2018 - 2030 (USD Million)
FIG. 56 Global plasmid DNA manufacturing market for others 2018 - 2030 (USD Million)
FIG. 57 Plasmid DNA manufacturing market: Disease outlook and key takeaways
FIG. 58 Global plasmid DNA manufacturing market: Disease movement analysis
FIG. 59 Global plasmid DNA manufacturing market for cancer 2018 - 2030 (USD Million)
FIG. 60 Global plasmid DNA manufacturing market for infectious diseases 2018 - 2030 (USD Million)
FIG. 61 Global plasmid DNA manufacturing market for genetic diseases 2018 - 2030 (USD Million)
FIG. 62 Regional marketplace: Key takeaway
FIG. 63 Plasmid DNA manufacturing market: Regional movement analysis
FIG. 64 North America plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 65 U.S. plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 66 Canada plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 67 Europe plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 68 Germany plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 69 U.K. plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 70 France plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 71 Spain plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 72 Italy plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 73 Spain plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 74 Asia Pacific plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 75 Japan plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 76 China plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 77 India plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 78 Australia plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 79 South Korea plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 80 Latin America plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 81 Brazil plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 82 Mexico plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 83 Middle East and Africa plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 84 South Africa plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 85 Saudi Arabia plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 86 UAE plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 87 New developments-based initiatives by key market participants
FIG. 88 Impact analysis of new developments by key market participants
FIG. 89 Company/competition categorization
FIG. 90 Distribution by location of manufacturing facility
FIG. 91 Distribution by scale of production
FIG. 92 Company mapping analysis
FIG. 93 Key public companies: Heat map analysis
FIG. 94 Synergy analysis: Major deals & strategic alliances
FIG. 95 Participant categorization
FIG. 96 Strategy framework
FIG. 97 SWOT analysis Charles River Laboratories
FIG. 98 SWOT analysis VGXI, Inc
FIG. 99 SWOT analysis Aldevron
FIG. 100 SWOT analysis KANEKA CORPORATION
FIG. 101 SWOT analysis Nature Technology
FIG. 102 SWOT analysis Cell and Gene Therapy Catapult
FIG. 103 SWOT analysis Eurofins
FIG. 104 SWOT analysis Lonza
FIG. 105 SWOT analysis Luminous BioSciences, LLC
FIG. 106 SWOT analysis Akron Biotech
FIG. 1 Market research process
FIG. 2 Market snapshot, 2021 (USD Million)
FIG. 3 Market research process
FIG. 4 Information procurement
FIG. 5 Primary research pattern
FIG. 6 Primary research pattern
FIG. 7 Market research approaches
FIG. 8 Value-chain-based sizing & forecasting
FIG. 9 QFD modeling for market share assessment
FIG. 10 Market formulation & validation
FIG. 11 QFD model assessment for plasmid DNA type
FIG. 12 Gene therapy approvals versus clinical trials
FIG. 13 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
FIG. 14 Distribution of the sponsors of advanced therapies clinical trials, 2016
FIG. 15 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
FIG. 16 Gene therapy approvals versus clinical trials
FIG. 17 Regional analysis for rare disease genetic testing market
FIG. 18 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
FIG. 19 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2021
FIG. 20 Market trends & outlook
FIG. 21 Market segmentation & scope
FIG. 22 Market driver relevance analysis (Current & future impact)
FIG. 23 Gene therapy clinical trials
FIG. 24 Viral vectors used in clinical trials
FIG. 25 Key strategies by market players to drive success in gene therapy arena
FIG. 26 Recent and upcoming approved gene transfer-mediated programs
FIG. 27 Market restraint relevance analysis (Current & future impact)
FIG. 28 Various ethical questions raised by gene therapy
FIG. 29 Major challenges in large-scale vector manufacturing
FIG. 30 Plasmid production: Challenges & solutions
FIG. 31 Penetration & growth prospect mapping for vector type, 2021
FIG. 32 Porter’s Five Forces Analysis
FIG. 33 SWOT analysis, by factor (Political & Legal, Economic and Technological)
FIG. 34 Penetration & growth prospect mapping for prominent industry players, 2021
FIG. 35 Plasmid DNA Manufacturing Landscape
FIG. 36 List of plasmid DNA manufacturers
FIG. 37 Comparison of costs estimated by campaign, day rate, and hybrid models
FIG. 38 Campaign model for viral vector production
FIG. 39 Gene Therapy Manufacturing Facilities: Trends & Types
FIG. 40 Gene Therapy Road Map: Key External Trends
FIG. 41 Strategic Approaches for Market Scale-Up
FIG. 42 Plasmid DNA manufacturing market: Grade outlook key takeaways
FIG. 43 Plasmid DNA manufacturing market: Grade movement analysis
FIG. 44 Global R & D market 2018 - 2030 (USD Million)
FIG. 45 Global GMP market 2018 - 2030 (USD Million)
FIG. 46 Plasmid DNA manufacturing market: Development phase outlook and key takeaways
FIG. 47 Global plasmid DNA manufacturing market: Development phase movement analysis
FIG. 48 Global pre-Clinical therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 49 Global clinical therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 50 Global marketed therapeutics market estimates and forecast 2018 - 2030 (USD Million)
FIG. 51 Plasmid DNA manufacturing market: Application outlook and key takeaways
FIG. 52 Plasmid DNA manufacturing market: Application movement analysis
FIG. 53 Global plasmid DNA manufacturing market for DNA vaccines 2018 - 2030 (USD Million)
FIG. 54 Global plasmid DNA manufacturing market for cell and gene therapy 2018 - 2030 (USD Million)
FIG. 55 Global plasmid DNA manufacturing market for immunotherapy 2018 - 2030 (USD Million)
FIG. 56 Global plasmid DNA manufacturing market for others 2018 - 2030 (USD Million)
FIG. 57 Plasmid DNA manufacturing market: Disease outlook and key takeaways
FIG. 58 Global plasmid DNA manufacturing market: Disease movement analysis
FIG. 59 Global plasmid DNA manufacturing market for cancer 2018 - 2030 (USD Million)
FIG. 60 Global plasmid DNA manufacturing market for infectious diseases 2018 - 2030 (USD Million)
FIG. 61 Global plasmid DNA manufacturing market for genetic diseases 2018 - 2030 (USD Million)
FIG. 62 Regional marketplace: Key takeaway
FIG. 63 Plasmid DNA manufacturing market: Regional movement analysis
FIG. 64 North America plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 65 U.S. plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 66 Canada plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 67 Europe plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 68 Germany plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 69 U.K. plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 70 France plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 71 Spain plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 72 Italy plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 73 Spain plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 74 Asia Pacific plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 75 Japan plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 76 China plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 77 India plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 78 Australia plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 79 South Korea plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 80 Latin America plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 81 Brazil plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 82 Mexico plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 83 Middle East and Africa plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 84 South Africa plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 85 Saudi Arabia plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 86 UAE plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
FIG. 87 New developments-based initiatives by key market participants
FIG. 88 Impact analysis of new developments by key market participants
FIG. 89 Company/competition categorization
FIG. 90 Distribution by location of manufacturing facility
FIG. 91 Distribution by scale of production
FIG. 92 Company mapping analysis
FIG. 93 Key public companies: Heat map analysis
FIG. 94 Synergy analysis: Major deals & strategic alliances
FIG. 95 Participant categorization
FIG. 96 Strategy framework
FIG. 97 SWOT analysis Charles River Laboratories
FIG. 98 SWOT analysis VGXI, Inc
FIG. 99 SWOT analysis Aldevron
FIG. 100 SWOT analysis KANEKA CORPORATION
FIG. 101 SWOT analysis Nature Technology
FIG. 102 SWOT analysis Cell and Gene Therapy Catapult
FIG. 103 SWOT analysis Eurofins
FIG. 104 SWOT analysis Lonza
FIG. 105 SWOT analysis Luminous BioSciences, LLC
FIG. 106 SWOT analysis Akron Biotech
